Highlights of Our Growth

1913  Mochida was established by Ryokichi Mochida, and started production and marketing of Luestin (anti- luetic) and Ogoko (ophthalmic ointment).
1918  The Company was renamed Mochida Pharmaceutical Company.
1930  Pelanin (first estrogen preparation developed in Japan)
1945  The Company was incorporated.
1951  Sprase (first hyaluronidase preparation developed in Japan)
1954  Began overseas marketing with exports to Taiwan.
1956  Thrombin Mochida (hemostatic enzyme)
1959  Transferred focus of sales strategy to obstetrics and gynecology.
1962  Established the Immunology Division.
1963  Listed on the Second Section of the Tokyo Stock Exchange (TSE).
1964  Nobuo Mochida was appointed president. 
         Gonavis (Japan’s first immunological pregnancy test kit); Kimotab (anti-inflammatory)
1967  Completed the Research Laboratory in Oji.
1970  Established the Paramedical Division.  
         Gonavislide (pregnancy test kit); Uronase (fibrinolytic); Skina Babe (baby bath oil)
1972  Established the Medical Electronics and Equipment Division.  
         Completed the Shizuoka Plant.
1975  Listed on the First Section of the TSE.
1976  Completed the new headquarters office building in Yotsuya.
1978  Received a Noteworthy Invention Testimonial from the Science and Technology Agency for the Medilaser balance-type surgical laser head.
1979  Rocornal
1980  Developed monoclonal antibody technology for an immunodiagnostic test. 
         Medilaser-S
1981  Signed an agreement with Hayashibara Biochemical Laboratory, Inc. for joint research of interferon.
1982  Completed the Fuji Central Research Laboratory.
1983  Established the Mochida Memorial Foundation for Medical and Pharmaceutical Research.
1984  Nobuo Mochida was awarded the Medal with Purple Ribbon for research on the first surgical laser unit developed in Japan.  
         Arasena-A
1985  Ei Mochida was appointed president.  
         Miracil
1986  Florid®-F injection; Grandaxin
1987  Ei Mochida was awarded the Medal with Purple Ribbon for R&D activities on an immunochemo-diagnostic reagent.
1988  Signed an agreement with Taisho Pharmaceutical Co., Ltd., allowing that company to market Dermarin, an OTC drug for treating dermatomycosis. 
         Collage Soap series; Isoprinosine®; IFNα Mochida; IFNβ Mochida
1989  Finalized agreements with Upjohn Co. for developing and marketing its prostaglandin derivative. 
         Tecipul
1990  Susumu Watanabe was appointed president.  
         Concluded a marketing agreement with Matsushita Electric Industrial Co., Ltd. for the Medilaser-10S fiber-optic carbon dioxide surgical laser unit. 
         Epadel Capsule 300
1991  Commenced operations at the Otawara Plant.  
         Concluded agreement of an antimycotic agent with Imperial Chemical Industries, PLC. 
         Mammotec

1994  Additional indication for Epadel (for hyperlipidemia) was approved.

1995  Signed agreements with Smithkline Beecham Seiyaku K.K. for the co-marketing of Arasena-A.

1996  Signed agreements with Norian Corporation for the development and marketing in Japan of Norian SRS®; and with Dainippon Pharmaceutical Co., Ltd. for the co-marketing of Epadel in Japan. Commenced JELIS (EBM study for Epadel).

1997  Concluded distribution agreement with Ajinomoto Co., Inc. for Atelec®.


1999  Naoyuki Mochida was appointed president.

2000  Signed agreements with RIKEN for co-research in structural genomics.

2001  Signed agreements with 3M for the development and marketing of Aldara.

2002  Signed agreements with Aventis Pharma Ltd. for the distribution and co-promotion of Suprecur®; and with Lundbeck A/S for the co-development and co-marketing of escitalopram. Established the nutraceutical business. Obtained ISO 14001 certification for the Otawara Plant.


2004  Started operation of Mochida Medical Systems Co., Ltd.

2005  Started operation of Mochida Healthcare Co., Ltd.

2006  Started operation of Mochida Siemens Medical Systems Co., Ltd.

2007  Signed agreements with JCR Pharmaceuticals Co., Ltd. for co-development and commercialization of a cellular-based drug; with Novartis Pharma K.K. for co-promotion of Diovan® (agreement terminated end of 2008); and with United Therapeutics Corporation for the distribution of Remodulin®.

2008  Signed a license agreement with Wyeth Pharmaceuticals Inc. for TRPV1 antagonists (agreement terminated 2010).

2009  Signed a license agreement with Shire Pharmaceuticals Group plc (U.K.) for LIALDA®.

2010  Signed agreement with Fuji Pharma Co., Ltd. for co-development of G-CSF; and with Mitsubishi Tanabe Pharma Corporation for co-marketing of escitalopram.

2011  Signed a license agreement with Merck (MSD outside the United States and Canada) for the potential treatment for type-2 diabetes (agreement terminated 2015).

2012  Fastic®; FOSHU (food for specified health use) Glucorina

2013  Epadel switch-OTC drug; Collage B.K. Age series; Filgrastim BS Syringe for Inj. Mochida; Tramcet®

2014  Atedio®; Collage series; Trepres®